Get to know our clinical trials
Open-label, dose-finding human clinical trial to evaluate the safety and antitumor activity of GEN1056 in participants with advanced solid tumors
THE AIM OF THE STUDY IS TO FIND OUT WHETHER GEN1056 IS SAFE IN PARTICIPANTS WITH ADVANCED CANCER AND TO FIND OUT THE BEST DOSE AND DOSAGE OF THE DRUG.
- FIRST OPEN-LABEL, DOSE-FINDING HUMAN TRIAL TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF GEN1056 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Code EudraCT: 2022-001003-40
- Protocol number: GCT1056-01
- Promoter: Genmab A/S
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.